KR102412392B1 - Cheongwitang Composition - Google Patents

Cheongwitang Composition Download PDF

Info

Publication number
KR102412392B1
KR102412392B1 KR1020200079498A KR20200079498A KR102412392B1 KR 102412392 B1 KR102412392 B1 KR 102412392B1 KR 1020200079498 A KR1020200079498 A KR 1020200079498A KR 20200079498 A KR20200079498 A KR 20200079498A KR 102412392 B1 KR102412392 B1 KR 102412392B1
Authority
KR
South Korea
Prior art keywords
weight
parts
composition
action
present
Prior art date
Application number
KR1020200079498A
Other languages
Korean (ko)
Other versions
KR20220001553A (en
Inventor
강기원
Original Assignee
강기원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강기원 filed Critical 강기원
Priority to KR1020200079498A priority Critical patent/KR102412392B1/en
Publication of KR20220001553A publication Critical patent/KR20220001553A/en
Application granted granted Critical
Publication of KR102412392B1 publication Critical patent/KR102412392B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/89Cyperaceae (Sedge family)
    • A61K36/8905Cyperus (flatsedge)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/63Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888Pinellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9062Alpinia, e.g. red ginger or galangal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 청위탕 조성물에 관한 것으로, 더욱 상세하게는 약재의 열수추출물을 유효성분으로 포함하되, 상기 약재는 향부자, 창출, 진피, 후박, 반하, 적복령, 연교, 나복자, 지실, 황금 및 황련을 포함하며, 식품 조성물인 것을 특징으로 한다. 본 발명에 의하면, 간편하게 섭취할 수 있고, 오랜 기간 섭취하더라도 인체에 무해할 뿐 아니라, 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제할 수 있는 효과가 있다.The present invention relates to a cheongwi-tang composition, and more particularly, it contains a hot water extract of medicinal herbs as an active ingredient, wherein the medicinal ingredients include hyangbuja, chrysanthemum, dermis, hubark, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon. Including, characterized in that the food composition. According to the present invention, it can be easily ingested and is not only harmless to the human body even when consumed for a long period of time, but also has the effect of suppressing damage to esophageal cells and inflammatory reaction caused by acid reflux.

Description

청위탕 조성물{Cheongwitang Composition}Cheongwitang Composition

본 발명은 청위탕 조성물에 관한 것으로, 더욱 상세하게는 향부자, 창출, 진피, 후박, 반하, 적복령, 연교, 나복자, 지실, 황금 및 황련의 추출물을 유효성분으로 함유하는 청위탕 조성물에 관한 것이다. The present invention relates to a cheongwi-tang composition, and more particularly, to a cheongwi-tang composition comprising extracts of hyangbuja, chrysanthemum, dermis, hubak, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon as active ingredients.

역류성 식도염(GRD: gastroesophageal reflux disease)은 유럽이나 미국과 같은 서구에서는 오래전부터 흔한 질환이었는데 최근 식생활이나 생활습관의 서구화에 따라 우리나라에서도 점차 증가하고 있다.Gastroesophageal reflux disease (GRD) has been a common disease in Western countries such as Europe and the United States for a long time.

가슴앓이가 가장 흔한 역류성 식도염의 증상이다. 이는 대개 명치 끝에서 목구멍 쪽으로 치밀어 오르는 듯한 타는 통증, 화끈거림, 쓰라린 느낌 또는 불쾌감을 말한다. 이 증상은 등이나 목 쪽으로 뻗칠 수 있으며 음식을 삼키기 어렵다고 느끼는 연하곤란과 함께 나타날 수 있다.Heartburn is the most common symptom of reflux esophagitis. This usually refers to a burning pain, burning, bitterness, or discomfort that seems to rise from the tip of the cervix to the throat. These symptoms may radiate to the back or neck and may be accompanied by dysphagia, a feeling of difficulty swallowing food.

산 역류도 중요한 증상인데 이는 신물이나 쓴 물 혹은 소화된 음식물이 다시 입으로 넘어오는 것을 말한다. 때로는 가슴이 아프거나 음식이 걸리는 느낌이 발생하기도 하고 음식을 먹지 않을 때에도 목에 덩어리가 있다고 느끼기도 한다. 상복부(오목가슴)의 반복적인 통증이나 불편감 혹은 만성적인 기침도 역류성 식도염의 증상일 수 있다.Acid reflux is also an important symptom, which refers to the return of sour, bitter, or digested food back into the mouth. Sometimes you may experience chest pain or a feeling of choking, and you may feel like you have a lump in your throat even when you are not eating. Repetitive pain or discomfort in the upper abdomen (concave chest) or a chronic cough may also be symptoms of reflux esophagitis.

역류성 식도염의 가슴앓이는 하루 중 언제나 생길 수 있지만 주로 식사 후 혹은 누운 자세에서 심해지는 것이 중요한 특징이다. 흔히 속쓰림과 혼동되기도 하는데 이는 기능성 소화불량이나 위궤양 혹은 십이지장 궤양에서 더욱 자주 나타나는 증상으로 식사 전, 즉 속이 비었을때 상복부(오목 가슴)의 증상이 심해지는 경향이 있다. 따라서 역류성 식도염의 증상과 속쓰림은 매우 비슷하지만 그 위치와 발생하는 시간에 다소 차이가 있다.Heartburn in gastroesophageal reflux disease can occur at any time of the day, but it is an important characteristic that it worsens mainly after eating or in a supine position. It is often confused with heartburn, but it is a symptom that appears more frequently in functional indigestion, gastric ulcer or duodenal ulcer. Therefore, the symptoms and heartburn of reflux esophagitis are very similar, but the location and time of onset are slightly different.

이 질환의 가장 큰 문제는 증상이 한번 생기면 대개 만성적으로 발전해 삶의 질을 떨어뜨릴 수 있다는 것이다. 즉, 목 이물감이 지속되면 만성 기침은 물론 이를 분해하기 위해 세균이 작용하며 구취가 발생해 단체생활에 지장을 받기도 하고, 누워있을 때 주로 증상이 생기기 때문에 가슴이 답답해 숙면을 취하기 어렵다. 또한, 역류성 식도염의 경우, 방치하면 드물지만 식도협착이나 식도암 등으로 발전할 수도 있다. 따라서 증상이 느껴지면 병원을 찾아 정확한 진단을 받고 치료를 하는 것이 무엇보다 중요하다. 특히, 단순히 위산을 억제하는 약물치료는 약을 중단하거나 용량을 줄이면 증상이 재발하는 경우가 많아 근본적인 치료와 식이 조절이 필요하다.The biggest problem with this disease is that once symptoms appear, they can often develop chronically and reduce quality of life. In other words, if the feeling of a foreign body in the throat persists, as well as chronic cough, bacteria act to break it down, and bad breath occurs, which interferes with group life. In addition, in the case of reflux esophagitis, if left untreated, it may develop into esophageal stricture or esophageal cancer, although rare. Therefore, it is of utmost importance to visit a hospital for an accurate diagnosis and treatment when symptoms are felt. In particular, in drug treatment that simply suppresses gastric acid, symptoms often recur when the drug is stopped or the dose is reduced, so fundamental treatment and dietary adjustment are necessary.

역류성 식도염의 치료에는 위산의 분비를 억제하는 여러 가지 약제가 사용되며, 가장 흔히 처방되는 약제는 오메프라졸이나 라베프라졸과 같은 수소펌프 억제제이다. 이는 위산의 분비를 90% 이상 줄임으로써 비록 역류가 계속 일어나더라도 증상이 발생하지 않고 식도의 병변이 진행하는 것을 막아준다. 식도와 하부식도 괄약근의 운동성을 조절하는 약들도 사용되고 있으며, 위의 약제를 함께 사용하는 경우도 있다. 잔탁(Zantac), 마일란타(Mylanta) 같은 약물을 사용하여 위산의 분비를 억제하거나 위산 위에 막을 씌워 위산이 올라오더라도 그 막이 식도를 미리 감싸 염증을 가라앉힌다. 염증 질환이라고 비스테로이드성 항염제(Non-steroidal Antiinflammatory Drugs)를 사용하면 해당 항염제에 있는 위산분비 효과로 인해 속쓰림 등의 생길 수 있다. 아스피린, 부루펜(ibuprofen) 등의 약이 이에 속한다.Various drugs that suppress gastric acid secretion are used for the treatment of reflux esophagitis, and the most commonly prescribed drugs are hydrogen pump inhibitors such as omeprazole or rabeprazole. This reduces the secretion of gastric acid by more than 90% and prevents the progression of esophageal lesions without causing symptoms even if reflux continues. Drugs that control the motility of the esophagus and lower esophageal sphincter are also used, and in some cases, the above drugs are used together. Drugs such as Zantac and Mylanta are used to suppress the secretion of gastric acid, or to cover the stomach acid with a membrane, which covers the esophagus in advance to relieve inflammation. If non-steroidal anti-inflammatory drugs are used as inflammatory diseases, heartburn may occur due to the gastric acid secretion effect of the anti-inflammatory drugs. These include medications such as aspirin and ibuprofen.

위의 여러 방법으로도 증상의 호전이 없는 경우에는 수술을 권유받게 된다. 몇가지 합병증이 생겨서 수술을 받는 경우도 있지만 이런 경우는 매우 드문 편이다. 최근에는 배나 가슴을 열지 않고 복강경을 이용한 수술법이 개발되어 있다.If symptoms do not improve despite the above methods, surgery is recommended. There are some cases where surgery is required because of some complications, but these cases are very rare. Recently, a surgical method using a laparoscopy without opening the abdomen or chest has been developed.

그러나 상기와 같은 화학합성 약물치료는 장기간 치료시에 인체에 좋지 않은 영향을 끼칠 수 있으며, 수술요법은 환자에게 큰 부담을 주며, 효과도 탁월하지 않은 단점이 있다.However, the chemical synthetic drug treatment as described above may have an adverse effect on the human body during long-term treatment, and surgery has a disadvantage in that it places a great burden on the patient and the effect is not excellent.

삭제delete

삭제delete

KR 10-1808328 B1KR 10-1808328 B1 KR 10-2082860 B1KR 10-2082860 B1 KR 10-1789392 B1KR 10-1789392 B1

따라서, 본 발명의 목적은 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제할 수 있는 청위탕 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a cheongwi-tang composition capable of inhibiting esophageal cell damage and inflammatory response due to acid reflux.

또한, 천연물 유래의 추출물을 유효성분으로 함으로써, 부작용이 없으며, 장기간 섭취가 가능한 청위탕 조성물을 제공하는 것이다.In addition, by using an extract derived from a natural product as an active ingredient, there is no side effect, and it is to provide a Cheongwi-tang composition that can be consumed for a long time.

상기한 목적을 달성하기 위한 본 발명의 청위탕 조성물은, 약재의 열수추출물을 유효성분으로 포함하되, 상기 약재는 향부자, 창출, 진피, 후박, 반하, 적복령, 연교, 나복자, 지실, 황금 및 황련을 포함하며, 식품 조성물인 것을 특징으로 한다. The Cheongwi-tang composition of the present invention for achieving the above object includes, as an active ingredient, a hot water extract of medicinal herbs, wherein the medicinal herbs are Hyangbuja, Genesis, Dermis, Hubak, Banha, Jeokbokryeong, Yeongyo, Nabokja, Jisil, Golden and Hwangryeon. It is characterized in that it comprises a food composition.

상기 약재는, 상기 향부자 100중량부에 대하여, 창출 25~40중량부, 진피 25~40중량부, 후박 25~40중량부, 반하 25~40중량부, 적복령 25~40중량부, 연교 25~40중량부, 나복자 25~40중량부, 지실 25~40중량부, 황금 20~30중량부 및 황련 20~30중량부를 포함하는 것을 특징으로 한다.The medicine is, with respect to 100 parts by weight of the hyangbuja, creation 25-40 parts by weight, dermis 25-40 parts by weight, husk 25-40 parts by weight, banha 25-40 parts by weight, Jeokbokryeong 25-40 parts by weight, Yeongyo 25- It is characterized in that it contains 40 parts by weight, 25-40 parts by weight of licorice root, 25-40 parts by weight of licorice, 20-30 parts by weight of gold and 20-30 parts by weight of yellow lily.

상기 약재는 민들레꽃 10~20중량부 및 달맞이꽃 10~20중량부를 더 포함하는 것을 특징으로 한다. The medicine is characterized in that it further comprises 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose.

상기 약재는 고량강 10~20중량부, 소루쟁이 뿌리 10~20중량부, 오수유 10~20중량부, 도꼬마리 열매 10~20중량부 중 1종 이상을 더 포함하는 것을 특징으로 한다.The medicinal material is characterized in that it further comprises at least one of 10 to 20 parts by weight of goryanggang, 10 to 20 parts by weight of herbarium root, 10 to 20 parts by weight of osuyu, and 10 to 20 parts by weight of blackberry fruit.

본 발명에 의한 청위탕 조성물은, 간편하게 복용할 수 있고, 오랜 기간 섭취하더라도 인체에 무해할 뿐 아니라, 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제할 수 있는 효과가 있다.The Cheongwi-tang composition according to the present invention can be easily taken, is harmless to the human body even when consumed for a long period of time, and has the effect of inhibiting esophageal cell damage and inflammatory reaction due to gastric acid reflux.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 가장 큰 특징은 천연 약재의 추출물만으로 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제할 수 있다는 점이다. 즉, 본 발명에 의한 청위탕 조성물이란, 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제할 수 있는 효과를 갖는 조성물을 의미하는 것으로, 이러한 조성물은 식품 조성물일 수 있다. 구체적으로, 본 발명의 청위탕 조성물은 음료, 액상차 등의 식품 형태로 제공될 수 있다. 또한, 분말, 환 등의 공지된 다양한 형태로 제공될 수 있다.The greatest feature of the present invention is that only extracts of natural medicinal substances can inhibit esophageal cell damage and inflammatory response due to acid reflux. That is, the Cheongwi-tang composition according to the present invention refers to a composition having an effect of inhibiting esophageal cell damage and inflammatory reaction caused by acid reflux, and the composition may be a food composition. Specifically, the Cheongwi-tang composition of the present invention may be provided in the form of food, such as a beverage or liquid tea. In addition, it may be provided in various known forms such as powder, pills, and the like.

아울러, 본 발명에 의한 조성물은 약재의 추출물만으로 구성될 수도 있고, 제형화를 위해 공지된 다양한 종류의 첨가제가 첨가될 수도 있다. 다만, 각종 첨가제가 첨가되더라도 상기 약재 추출물이 전체 조성물 100중량%에 대하여 10중량% 이상, 즉 10~100중량%의 범위 내에서 사용되도록 한다.In addition, the composition according to the present invention may consist only of extracts of medicinal substances, and various types of additives known for formulation may be added. However, even if various additives are added, the medicinal extract is used within the range of 10% by weight or more, that is, 10 to 100% by weight based on 100% by weight of the total composition.

이를 위한 본 발명의 청위탕 조성물은, 약재의 열수추출물을 유효성분으로 포함하되, 상기 약재는 향부자, 창출, 진피, 후박, 반하, 적복령, 연교, 나복자, 지실, 황금 및 황련를 포함하는 것을 특징으로 한다.For this purpose, the Cheongwi-tang composition of the present invention includes a hot water extract of medicinal herbs as an active ingredient, wherein the medicinal materials include hyangbuja, chrysanthemum, dermis, hubak, banha, jeokbokryeong, yeonkyo, nabokja, jisil, gold and hwangryeon. do.

상기 약재에 대해 간략히 살펴보면, 상기 향부자는 사초과에 속해있는 다년생 식물인 향부자의 뿌리줄기 부분을 말린 약재로, 신경성 위장병을 치료해 주고, 만성적 스트레스로 인해 생기는 소화불량을 치료해 준다고 알려져 있다. Briefly looking at the above medicinal materials, the Hyangbuja is a medicinal herb obtained by drying the rhizome of Hyangbuja, a perennial plant belonging to the family Saraceae, and is known to treat nervous gastrointestinal diseases and indigestion caused by chronic stress.

상기 창출은 삽주의 뿌리 열매를 건조한 것으로, 위장을 튼튼하게 하고 비만을 방지하며, 죽은 피부조직, 황달, 경련을 치료하고 땀을 멎게 하고 熱(열)을 제거하고, 음식을 소화시키는 역할을 한다.The above creation is the dried root fruit of sapju, which strengthens the stomach and prevents obesity, treats dead skin tissue, jaundice, and convulsions, stops sweating, removes heat, and digests food. .

상기 진피는 운향과의 귤(Citrus unshiu Markovich) 또는 동속 근연식물의 성숙한 과피를 건조한 것으로, 기가 뭉친 것을 풀어주고, 비장의 기능을 강화하여 복부창만, 트림, 구토, 메스꺼움, 소화불량, 헛배가 부르고 나른한 증상, 대변이 묽은 증상을 치료한다. 아울러, 해수, 가래를 없애주며 이뇨작용을 한다. 약리작용은 정유 성분이 소화기자극, 소화촉진, 거담, 항궤양, 항위액분비, 강심, 혈압상승, 항알레르기, 담즙분비촉진, 자궁평활근억제, 항균작용 등을 하는 것으로 보고되었다. The dermis is dried tangerine (Citrus unshiu Markovich) or the mature pericarp of a closely related plant of the rutaceae family, which releases agglomeration and strengthens the function of the spleen to cause stomach upset, belching, vomiting, nausea, indigestion, flatulence It treats the symptoms of drowsiness and loose stools. In addition, seawater, removes phlegm and acts as a diuretic. It has been reported that essential oil components have digestive stimulation, digestion promotion, expectorant, anti-ulcer, anti-gastric secretion, strong heart, blood pressure increase, anti-allergy, biliary secretion promotion, uterine smooth muscle suppression, and antibacterial action.

상기 후박은 목련과에 속하는 일본목련(Magnolia ovobata Thunberg), 후박(Magnolia officinalis Rehder et Wilson) 또는 요엽후박(凹葉厚樸, Magnolia officinalis Rehder et Wilson var. biloba Rehder et Wilson)의 줄기껍질을 건조한 것으로, 주요 활성성분은 리그난과 정유성분이다. 상기 후박은 항염 및 항균 효능이 뛰어나며, 위한증을 치료하고, 체한 것을 치료하며, 막혀있는 탁한 담을 쳐내리는 효능이 있다. 또한, 소화불량을 해소하고, 위염과 장염 치료에 많이 쓰이며, 장운동을 원활하게 해주는 역할을 한다. The sagebrush is a dried stem bark of Magnolia ovobata Thunberg, Magnolia officinalis Rehder et Wilson, or coniferous succulents (Magnolia officinalis Rehder et Wilson var. biloba Rehder et Wilson) belonging to the Magnolia family. The active ingredients are lignans and essential oils. The sagebrush has excellent anti-inflammatory and antibacterial effects, and has the effect of treating cough, treating body aches, and knocking down clogged turbid walls. In addition, it relieves indigestion, is often used in the treatment of gastritis and enteritis, and plays a role in facilitating bowel movements.

상기 반하는 천남성과의 반하(Pinellia ternata Breitenbach)의 코르크층을 제거한 덩이줄기를 건조한 것으로, 습담을 치료하므로 가래, 해수, 천식에 쓰이며, 담으로 인한 두통, 어지럼증, 가슴답답증, 그득한 증상, 구토, 인후통, 등 부위에 난 종기, 유방염, 임신구토 등에 사용한다. 상기 반하의 약리작용으로 거담, 진해, 구토진정, 규폐증예방, 항암작용 등이 보고되었다.The above-mentioned antibacterial (Pinellia ternata Breitenbach) is a dried tuber from which the cork layer has been removed. It is used for sputum, seawater, and asthma as it treats dampness. , It is used for boils on the back, mastitis, and vomiting during pregnancy. Expectorant, antitussive, vomiting sedation, silicosis prevention, anticancer action, etc. have been reported as the pharmacological actions of the antihas.

상기 적복령은 소나무에 기생하는 균체로, 소나무를 베고 나면 다시 싹이 나오지 않으나 그 뿌리는 죽지 않고 진액이 아래로 흘러내리므로 복령이 생긴다. 완만한 이뇨작용이 있어 소화기가 약하면서 전신에 부종이 있을 때에 효과가 뛰어나며 신장염, 방광염, 요도염에도 효과가 있다. 또한, 거담작용이 있어서 가래가 많이 분비되고 호흡이 곤란한 증상인 만성기관지염과 기관지확장증에도 거담 진해하는 약물과 배합하여 치료하고 있다. 이 밖에 건위작용이 있어서 위장 내에 수분이 과다하게 정체되어 복부가 팽만되고 구토를 일으키는 만성위장염에 쓰이며 진정효과가 뛰어나서 신경의 흥분으로 인한 초조와 불안, 자주 놀라고 입이 마르며 식은땀을 흘리는 증상에 안정제로 쓰인다.The jeokbokryeong is a parasitic bacterium on a pine tree, and after cutting a pine tree, sprouts do not come out again, but the root does not die and the sap flows down, so bokryeong occurs. It has a gentle diuretic effect, so it is effective when the digestive system is weak and there is edema all over the body. It is also effective in nephritis, cystitis, and urethritis. In addition, since it has an expectorant action, it is being combined with an expectorant antitussive drug to treat chronic bronchitis and bronchiectasis, which are symptoms that produce a lot of phlegm and have difficulty breathing. In addition, it has a gastric action, so it is used for chronic gastroenteritis that causes excessive water retention in the stomach to cause bloating and vomiting. is used as

상기 연교는 물푸레나무과의 의성개나리(Forsythia viridissima Lindley) 또는 당개나리(Forsythia suspensa Vahl)의 건조시킨 열매로, 열을 내리고 해독하며, 풍열(風熱)을 없애고, 종기나 상처가 부은 것을 삭도록 하거나 뭉치거나 몰린 것을 풀어주는 소종산결(消腫散結)하는 효능을 갖는다. 따라서 온열병 초기에 열을 내려서 고열과 정신이 혼몽한 것을 가라앉히거나, 종기, 림프절염, 인후염 등에 활용할 수 있다. 약리작용으로 항균작용, 항염증작용, 혈압강하, 지혈작용, 간 치료작용, 해열, 진토, 이뇨작용이 보고되었으며, 주요 화학성분으로는 포르시톨(forsythol), 스테롤(sterol) 화합물, 사포닌(saponin), 올레아놀산(oleanolic acid) 등이 있다.The Yeongyo is the dried fruit of Forsythia viridissima Lindley or Forsythia suspensa Vahl of the ash family. It has the effect of dissolving clumping or clumping. Therefore, it can be used for fever, lymphadenitis, sore throat, etc., or to relieve high fever and confusion by lowering heat in the early stages of fever. Antibacterial action, anti-inflammatory action, blood pressure lowering, hemostatic action, liver treatment action, antipyretic action, anti-emetic action, and diuretic action have been reported as pharmacological actions. saponin) and oleanolic acid.

상기 나복자는 십자화과의 무(Raphanus sativus L.) 또는 동속식물의 씨를 사용해 만든 약재로, 기를 통하게 하고 체한 것을 내려가게 하는 효능이 있어서 복부창만, 트림, 위산과다, 설사 등에 사용한다. 기를 내리고 가래를 삭히며 해수, 천식, 변비에 효과가 있다. 식욕부진을 치료하고, 오래된 담, 오래된 기침을 멈추게 하는 효과가 있다. 약리작용으로는 포도상구균 등의 억제작용, 피부 진균 억제작용, 혈압강하작용, 항염증작용 등이 보고되었다.The larvae are medicinal products made using the seeds of cruciferous radish (Raphanus sativus L.) or animals and plants, and have the effect of passing the qi and lowering the body. It lowers qi and removes phlegm, and is effective for seawater, asthma, and constipation. It is effective in treating anorexia and stopping old phlegm and old cough. As pharmacological action, inhibitory action against staphylococcus, etc., skin fungus suppression action, blood pressure lowering action, anti-inflammatory action, etc. have been reported.

상기 지실은 탱자나무(Poncirus trifoliata Rafin)의 덜 익은 열매를 말린 것으로, 몰린 기를 흩어지게 하고 소화를 도우며 가래를 삭인다. 약리 실험에서 자궁 수축 작용, 위장 연동 운동 항진 작용, 혈압 상승 작용, 강심(强心) 작용, 이뇨 작용 등이 밝혀졌다. 식체(食滯), 소화 장애, 복부 팽만, 변비, 이질, 자궁하수증, 위하수, 탈항, 위확장증, 위염 등에 사용된다.The branch is the dried unripe fruit of Poncirus trifoliata Rafin, which disperses the molybdenum, aids digestion, and removes phlegm. In pharmacological experiments, uterine contraction action, gastrointestinal peristalsis enhancing action, blood pressure increase action, cardiac action, and diuretic action were revealed. It is used for gastrointestinal disorders, digestive disorders, abdominal distension, constipation, dysentery, uterine fibroids, gastric pitting, prolapse, gastric dilatation, and gastritis.

상기 황금은 그 뿌리를 말린 약재로서, 바이카레인(Baicalein), 바이카린(Baicalin), 워고닌(Wogonin), 워고노사이드(Wogonoside) 등이 함유되어, 체내에 과다하게 쌓인 열을 해소해주고, 항염증 작용을 한다.The gold is a medicinal herb that has dried its roots, and contains Baicalein, Baicalin, Wogonin, Wogonoside, etc. to relieve excessive heat accumulated in the body, It has anti-inflammatory action.

상기 황련은 그 뿌리를 채취하여 건조한 것으로, 건위, 진정, 소염, 항균 등의 효능이 있어 소화불량, 위염, 장염, 복통, 구토, 이질, 심계(心悸), 번열(煩熱), 정신불안, 인후종통(咽喉腫痛), 토혈, 코피, 하혈, 화상 등의 치료에 처방한다. 열을 내리고 습사(濕邪)를 없애며, 화(火)를 말끔히 제거하고 해독한다. 약리 실험에서 주요 성분인 베르베린이 장내 세균에 대한 항균 작용, 진정 및 진경(鎭驚) 작용, 항동맥경화 작용, 소염작용, 이담(利膽) 작용, 췌장액 분비 촉진 작용을 나타낸다는 것이 밝혀졌다. The yellow lotus root is collected and dried, and has effects such as dryness, sedation, anti-inflammatory and antibacterial properties. It is prescribed for the treatment of sore throat (咽喉腫痛), hematemesis, nosebleeds, bleeding, and burns. It lowers heat, removes wet sand, and cleanly removes and detoxifies fire. In pharmacological experiments, it was found that berberine, the main ingredient, exhibits antibacterial action, sedative and antispasmodic action against intestinal bacteria, anti-arteriosclerosis action, anti-inflammatory action, biliary tract action, and pancreatic secretion promoting action.

본 발명은 이러한 약재들의 상호작용을 통해 위산 역류에 의한 식도 세포의 손상 및 염증반응을 억제하는 것이다.The present invention inhibits esophageal cell damage and inflammatory response due to acid reflux through the interaction of these drugs.

본 발명에서 상기 추출물이란, 약재의 열수추출물을 의미하는 것으로, 상기 열수추출물은 종래 게시된 통상의 방법에 따라 제조될 수 있으며, 예시적으로 약재에 5~30중량배의 물을 가하고, 이를 80~100℃로 5~40시간 가열하고, 여과함으로써, 제조될 수 있다. 또한, 이러한 추출물은 필요에 따라 여과하거나 농축 또는 건조과정을 수행하여 용매인 물을 제거할 수 있음은 당연하다.In the present invention, the extract refers to a hot-water extract of medicinal substances, and the hot-water extract can be prepared according to a conventionally published conventional method, illustratively by adding 5 to 30 times by weight of water to the medicinal material, and 80 It can be prepared by heating to ˜100° C. for 5 to 40 hours and filtering. In addition, it is natural that the extract can be filtered or concentrated or dried to remove water as a solvent, if necessary.

아울러, 상기 약재의 혼합비는 향부자 100중량부에 대하여 창출 25~40중량부, 진피 25~40중량부, 후박 25~40중량부, 반하 25~40중량부, 적복령 25~40중량부, 연교 25~40중량부, 나복자 25~40중량부, 지실 25~40중량부, 황금 20~30중량부 및 황련 20~30중량부를 포함하는 것이 바람직한바, 이는 각 약재의 성분, 약리작용, 항염 효과 등을 고려한 것이다.(이하, '중량부'는 상기 향부자 100중량부를 기준으로 한다.)In addition, the mixing ratio of the drug is 25-40 parts by weight of creation, 25-40 parts by weight of dermis, 25-40 parts by weight of squash, 25-40 parts by weight of Banha, 25-40 parts by weight of Jeokbokryeong, 25-40 parts by weight of Yeongyo with respect to 100 parts by weight of Hyangbuja It is preferable to include ~40 parts by weight, 25-40 parts by weight of licorice root, 25-40 parts by weight of licorice, 20-30 parts by weight of gold and 20-30 parts by weight of yellow lily, which is a component of each drug, pharmacological action, anti-inflammatory effect, etc. (Hereinafter, 'part by weight' is based on 100 parts by weight of the hyangbuja.)

한편, 상기 약재는 민들레꽃 10~20중량부 및 달맞이꽃 10~20중량부를 더 포함할 수 있다. 상기 민들레꽃은 민들레꽃의 건조물을, 상기 달맞이꽃은 달맞이꽃을 건조물을 의미하는바, 강력한 항균 및 항염 작용으로 식도 세포의 손상 및 염증반응을 더욱 효과적으로 억제해준다.On the other hand, the medicine may further include 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose. The dandelion flower refers to the dried product of the dandelion flower, and the evening primrose refers to the dried product of the evening primrose, and it more effectively inhibits damage and inflammation of esophageal cells with strong antibacterial and anti-inflammatory action.

아울러, 상기 약재는 고량강 10~20중량부, 소루쟁이뿌리 10~20중량부, 오수유 10~20중량부, 도꼬마리 열매 10~20중량부 중 1종 이상, 바람직하게는 4종 모두를 더 포함할 수 있다.In addition, the medicinal material further includes at least one of 10-20 parts by weight of goryanggang, 10-20 parts by weight of burdock root, 10-20 parts by weight of osuyu, and 10-20 parts by weight of sagebrush, preferably all four. can do.

상기 고량강(Alpinia officinarum)은 생강과에 속한 다년생 초본으로 뿌리줄기를 가을에 수확하여 건조한 것으로, 만성 위염, 복통, 구토 등에 사용하고 항혈전 및 항균작용이 있는 것으로 밝혀져 있는바, 강력한 항균 및 항혈전 작용을 갖는다.The goryanggang (Alpinia officinarum) is a perennial herb belonging to the ginger family, and the rhizomes are harvested in autumn and dried, used for chronic gastritis, abdominal pain, vomiting, etc. has thrombotic action.

상기 소루쟁이 뿌리는 트라퀴논(Anthraquinon) 유도체인 크리소파놀(Chrysophanol)과 에모딘(Emodin)이 함유되어 있어, 소화불량 등에 사용된다.The root of the blueberry contains Chrysophanol and Emodin, which are derivatives of traquinone (Anthraquinon), and is used for indigestion and the like.

상기 오수유는 운향과에 속한 오수유의 과실을 건조한 것으로, 항혈전 및 항염 작용이 우수하다. The Osuyu is a dried fruit of Osuyu belonging to the Unhyangwa family, and has excellent antithrombotic and anti-inflammatory properties.

상기 도꼬마리(Xanthium strumarium var. japonicum HARA) 열매는 진통, 산풍(散風), 거습(祛濕), 소종(消腫) 등의 효능이 보고되어 있는바, 본 발명에서 상기 약재는 식도 세포의 손상 및 염증반응을 더욱 효과적으로 억제해준다.The fruit of Xanthium strumarium var. japonicum HARA has been reported to have effects such as analgesia, mountain wind, dampness, small swelling, and the like, and in the present invention, the drug is used to damage esophageal cells. and more effectively inhibit the inflammatory response.

상기와 같은 본 발명의 조성물은, 각 약재들 간의 상호작용으로, 식도 세포의 손상 및 염증반응을 억제하는 것은 물론, 천연물 유래의 추출물을 유효성분으로 함으로써, 부작용이 없으며, 장기간 섭취가 가능하다.The composition of the present invention as described above has no side effects and can be consumed for a long time by not only inhibiting damage and inflammatory reaction of esophageal cells, but also using an extract derived from a natural product as an active ingredient by interaction between each drug.

본 발명에 따른 조성물의 바람직한 섭취량은 당 업자에 의해 적절하게 선택될 수 있는데, 예시적으로 본 발명에 따른 유효성분을 1일 0.0001~l00mg/kg으로, 하루에 한 번 섭취할 수도 있고, 수회 나누어 섭취할 수도 있으나, 이를 반드시 제한하는 것은 아니다.A preferred intake amount of the composition according to the present invention may be appropriately selected by those skilled in the art, for example, the active ingredient according to the present invention is 0.0001 to 100 mg/kg per day, and may be ingested once a day, or divided several times. It may be ingested, but it is not necessarily limited thereto.

이하, 본 발명을 실시예에 의해 상세히 설명하기로 한다.Hereinafter, the present invention will be described in detail by way of Examples.

(실시예 1)(Example 1)

향부자 120g에 대하여, 창출 40g, 진피 40g, 후박 40g, 반하 40g, 적복령 40g, 연교 40g, 나복자 40g, 지실 40g, 황금 28g 및 황련 28g의 약재에 물 10kg을 80~100℃에서 20시간 추출한 후, 여과하였다.For 120 g of Hyangbuja, 10 kg of water was extracted from medicinal herbs of 40 g of Chrysanthemum, 40 g of dermis, 40 g of squash, 40 g of Banha, 40 g of Jeokbokryeong, 40g of Yeongyo, 40g of Nabokja, 40g of Jisil, 28g of golden lily and 28g of Hwangryeon at 80~100℃ for 20 hours. filtered.

(실시예 2)(Example 2)

실시예 1과 동일하게 실시하되, 민들레꽃 15g 및 달맞이꽃 15g을 약재로서 더 사용하였다. It was carried out in the same manner as in Example 1, except that 15 g of dandelion flowers and 15 g of evening primrose were further used as medicinal materials.

(실시예 3)(Example 3)

실시예 2와 동일하게 실시하되, 고량강 15g, 소루쟁이뿌리 15g, 오수유 15g 및 도꼬마리 열매 15g을 약재로서 더 사용하였다.It was carried out in the same manner as in Example 2, except that 15 g of goryanggang, 15 g of turmeric root, 15 g of osuyu and 15 g of blackberry fruit were further used as medicinal materials.

(시험예 1)(Test Example 1)

염산은 위산의 주성분으로 역류성 식도염은 위산 역류에 의한 식도 세포의 손상에 따른 염증반응에 의해 발생한다. 따라서, 상기 추출물이 염산에 의한 식도 세포 손상을 억제하는지에 관한 시험관 시험을 실시하였다. 이때, 각 추출물은 감압농축 및 동결건조하여 사용하였다.Hydrochloric acid is the main component of gastric acid, and reflux esophagitis is caused by an inflammatory reaction caused by damage to esophageal cells caused by acid reflux. Therefore, an in vitro test was conducted on whether the extract inhibits esophageal cell damage caused by hydrochloric acid. At this time, each extract was concentrated under reduced pressure and freeze-dried.

먼저, 인간 식도 세포 Het-1a는 ATCC(American Type Culture Collection)에서 구입하여 BEGM™ 배지(Lonza)를 사용하여 37℃, 5% CO2 배양기에서 배양하였다. 상기 배양된 인간 식도 세포인 Het-1a 세포를 96 웰 플레이트(well plate)에 2×104cells/well로 분주하여 24시간 배양한 후, 상기 각 추출물 10μg/mL와 염산을 최종농도가 각각 10mM이 되도록 처리하였다. 상기 염산처리 6시간 후, MTT 용액(SIGMA, M5655)을 넣고 1시간 더 배양한 다음, 생성된 포르마잔(formazan)을 디메틸술폭시드(dimethyl sulfoxide; DMSO)를 첨가하여 용해시키고, 540nm에서 흡광도를 측정하여 세포생존율을 측정하였다.First, human esophageal cells Het-1a were purchased from ATCC (American Type Culture Collection) and cultured in a 37° C., 5% CO 2 incubator using BEGM™ medium (Lonza). The cultured human esophageal cells, Het-1a cells, were dispensed in a 96-well plate at 2×10 4 cells/well and cultured for 24 hours, and then 10 μg/mL of each extract and hydrochloric acid were added to a final concentration of 10 mM, respectively. processed to be this. After 6 hours of the hydrochloric acid treatment, MTT solution (SIGMA, M5655) was added and incubated for an additional hour, then the generated formazan was dissolved by adding dimethyl sulfoxide (DMSO), and absorbance at 540 nm was obtained. By measuring the cell viability was measured.

한편, 대조군에는 상기 추출물 대신에 동량의 PBS(phosphate buffered saline)을 처리한 것 외에는 상기와 동일한 방법으로 실험하였다.On the other hand, the control group was tested in the same manner as above except that the same amount of phosphate buffered saline (PBS) was treated instead of the extract.

그 결과를 하기 표 1에 나타내었다.The results are shown in Table 1 below.

시험예 1 결과Test Example 1 Results 구분division 세포생존율(%)Cell viability (%) 실시예 1Example 1 90.190.1 실시예 2Example 2 91.791.7 실시예 3Example 3 92.592.5 대조군 control 75.875.8

상기 표 1에서 확인할 수 있는 바와 같이, 대조군에서는 약 25%의 세포사멸이 이루어진 반면, 본 발명의 실시예 1 내지 3은 식도 세포의 사멸이 크게 줄어드는 것을 확인할 수 있었다.As can be seen in Table 1, in the control group, about 25% of apoptosis was achieved, whereas in Examples 1 to 3 of the present invention, it was confirmed that the death of esophageal cells was significantly reduced.

(시험예 2)(Test Example 2)

산에 의한 식도 세포의 염증반응에는 염증성 싸이토카인인 IL-6가 중요한 인자로 보고되어 있다. 따라서, 상기 각 추출물이 산에 의해 증가하는 IL-6를 억제하여 식도 세포 염증반응을 억제하는지에 관한 시험관 시험을 실시하였다. 이때, 각 추출물은 감압농축 및 동결건조하여 사용하였다.It has been reported that IL-6, an inflammatory cytokine, is an important factor in the inflammatory response of esophageal cells by acid. Therefore, an in vitro test was performed on whether each of the extracts inhibits the esophageal cell inflammatory response by inhibiting IL-6 increased by acid. At this time, each extract was concentrated under reduced pressure and freeze-dried.

인간 식도 세포인 Het-1a 세포를 96 웰 플레이트(well plate)에 2×104 cells/well로 분주하여 24시간 배양한 후, 상기 각 추출물을 최종농도가 10㎍/㎖이 되도록 처리하였다. 상기 추출물의 처리 1시간 후, 배지를 제거하고 염산을 첨가하여 배지의 pH를 7.2에서 4.5로 낮춘 배지로 교환하였다. pH 4.5 배지 처리 1시간 후 다시 배지를 제거하고 pH 7.2의 일반 배지로 교환한 다음, 6시간 동안 37℃, 5% CO2 배양기에서 세포를 배양하였다. 배양 6시간 후 세포를 PBS(phosphate buffered saline)로 3회 세척한 다음, trizol reagent(sigma)를 각 well에 처리하여 total RNA를 분리하였다. 분리된 total RNA는 정량 후 동량을 취하여 High Capacity cDNA Kit(thermofisher)을 이용하여 cDNA를 합성한 다음, SYBR Premix Ex Taq™(Takara) 및 IL-6 primer(Hs00174131_m1, thermofisher)를 사용하여 qPCR을 시행하여 IL-6의 상대적 발현량을 측정하였다.Het-1a cells, which are human esophageal cells, were aliquoted in a 96-well plate at 2×10 4 cells/well and cultured for 24 hours, and then each extract was treated to a final concentration of 10 μg/ml. After 1 hour of treatment with the extract, the medium was removed and the medium was replaced with a medium in which the pH of the medium was lowered from 7.2 to 4.5 by the addition of hydrochloric acid. After 1 hour of pH 4.5 medium treatment, the medium was removed again and replaced with a normal medium of pH 7.2, and then the cells were cultured in a 37° C., 5% CO 2 incubator for 6 hours. After 6 hours of incubation, the cells were washed 3 times with PBS (phosphate buffered saline), and then treated with trizol reagent (sigma) in each well to isolate total RNA. After quantification, the same amount of isolated total RNA was taken and cDNA was synthesized using the High Capacity cDNA Kit (thermofisher), and then qPCR was performed using SYBR Premix Ex Taq™ (Takara) and IL-6 primer (Hs00174131_m1, thermofisher). Thus, the relative expression level of IL-6 was measured.

한편, 대조군은 pH4.5 배지를 처리하지 않고, 상기 추출물을 처리하지 않은 것을 제외하고는 상기와 동일한 방법으로 실험하였으며, 양성 대조군은 상기 추출물을 처리하지 않은 것을 제외하고는 상기와 동일한 방법으로 실험하였다.On the other hand, the control group was tested in the same manner as above except that the pH4.5 medium was not treated and the extract was not treated, and the positive control group was tested in the same way as above except that the extract was not treated. did

그 결과를 하기 표 2에 나타내었다.The results are shown in Table 2 below.

시험예 2 결과Test Example 2 Results 구분division 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 양성 대조군positive control 대조군control IL-6 expression(Fold)IL-6 expression (Fold) 3.743.74 3.513.51 3.153.15 5.215.21 1One

상기 표 2에서 확인할 수 있는 바와 같이, 본 발명의 양성 대조군의 경우 염산에 의해 IL-6의 발현이 크게 증가한 반면, 실시예 1 내지 3은 염산에 의한 IL-6의 발현이 줄어든 것을 확인할 수 있었다. 이는 위산이 역류하여 식도 세포를 자극했을 때 본 발명의 실시예 1 내지 3이 위산에 의한 염증반응을 유전자 단계에서 억제할 수 있음을 나타낸다.As can be seen in Table 2, in the case of the positive control of the present invention, the expression of IL-6 was greatly increased by hydrochloric acid, whereas in Examples 1 to 3, it was confirmed that the expression of IL-6 by hydrochloric acid was reduced. . This indicates that when gastric acid reflux stimulates esophageal cells, Examples 1 to 3 of the present invention can suppress the inflammatory response caused by gastric acid at the gene level.

(시험예 3)(Test Example 3)

역류성 식도염 증상이 있는 성인 남자 40명, 여자 40명을 피험군으로 하여 이를 남, 여 각 10명씩 네 그룹으로 나눈 후, 각 그룹당 상기 각 실시예 또는 비교예 1을 1일 3회 1회당 100g씩 8시간 간격으로 복용하게 하고, 복용 후 10일, 20일, 30일에 역류성 식도염의 개선 정도를 평가하고, 그 결과(20명의 평균치)를 하기 표 3에 나타내었다. 상기 비교예 1은 향부자 100g에 물 1kg을 가하고 80~100℃에서 20시간 추출한 후, 여과하여 제조하였다. 40 adult males and 40 females with symptoms of reflux esophagitis were divided into four groups of 10 males and females each as a test group, and 100g of each Example or Comparative Example 1 was administered 3 times a day for each group. They were given 8 hours apart, and the degree of improvement of reflux esophagitis was evaluated on the 10th, 20th, and 30th days after taking, and the results (average value of 20 patients) are shown in Table 3 below. In Comparative Example 1, 1 kg of water was added to 100 g of Hyangbuja, extracted at 80-100° C. for 20 hours, and filtered.

시험예 3 결과Test Example 3 Results 구분division 10일 후after 10 days 20일 후after 20 days 30일 후30 days later 실시예 1Example 1 2.72.7 3.53.5 4.84.8 실시예 2Example 2 2.82.8 3.73.7 5.05.0 실시예 3Example 3 3.03.0 4.24.2 5.35.3 비교예 1Comparative Example 1 2.12.1 2.52.5 2.72.7 <평가기준>
6: 100% 개선됨, 5: 80% 개선됨,
4: 50% 개선됨, 3: 20% 개선됨,
2: 변화 없음, 1: 악화됨
<Evaluation criteria>
6: 100% improvement, 5: 80% improvement,
4: 50% improvement, 3: 20% improvement,
2: No change, 1: Worse

상기 표 3에서 확인할 수 있는 바와 같이, 본 발명의 조성물은 명백히 우수한 역류성 식도염 개선효과를 얻은 것으로 확인되었다.As can be seen in Table 3 above, it was confirmed that the composition of the present invention clearly improved the effect of improving reflux esophagitis.

(시험예 4)(Test Example 4)

담적병 증상이 있는 성인 남자 20명, 여자 20명을 피험군으로 하여 이를 남, 여 각 5명씩 네 그룹으로 나눈 후, 각 그룹당 상기 각 실시예 또는 비교예 1을 1일 3회 1회당 100g씩 8시간 간격으로 복용하게 하고, 복용 후 10일, 20일, 30일에 담적병의 개선 정도를 평가하고, 그 결과(10명의 평균치)를 하기 표 4에 나타내었다. 상기 비교예 1은 향부자 100g에 물 1kg을 가하고 80~100℃에서 20시간 추출한 후, 여과하여 제조하였다. 20 adult males and 20 females with symptoms of cholestasis were divided into four groups of 5 males and females each, and 100g each of the Examples or Comparative Example 1 3 times a day for each group They were given at intervals of 8 hours, and the degree of improvement of cholestasis was evaluated on the 10th, 20th, and 30th days after taking, and the results (average value of 10 patients) are shown in Table 4 below. In Comparative Example 1, 1 kg of water was added to 100 g of Hyangbuja, extracted at 80-100° C. for 20 hours, and filtered.

시험예 4 결과Test Example 4 Results 구분division 10일 후after 10 days 20일 후after 20 days 30일 후30 days later 실시예 1Example 1 2.12.1 2.92.9 4.14.1 실시예 2Example 2 2.42.4 3.43.4 4.84.8 실시예 3Example 3 2.72.7 4.44.4 5.95.9 비교예 1Comparative Example 1 2.02.0 2.22.2 2.52.5 <평가기준>
6: 100% 개선됨, 5: 80% 개선됨,
4: 50% 개선됨, 3: 20% 개선됨,
2: 변화 없음, 1: 악화됨
<Evaluation criteria>
6: 100% improvement, 5: 80% improvement,
4: 50% improvement, 3: 20% improvement,
2: No change, 1: Worse

상기 표 3에서 확인할 수 있는 바와 같이, 본 발명의 조성물은 명백히 우수한 담적병 개선효과를 얻은 것으로 확인되었다.As can be seen in Table 3 above, it was confirmed that the composition of the present invention clearly obtained an excellent effect of improving gallbladder disease.

본 발명을 바람직한 실시예를 사용하여 상세히 설명하였으나, 본 발명의 범위는 특정 실시예에 한정되는 것은 아니며, 첨부된 특허청구범위에 의하여 해석되어야 할 것이다. 또한, 이 기술분야에서 통상의 지식을 습득한 자라면, 본 발명의 범위에서 벗어나지 않으면서도 많은 수정과 변형이 가능함을 이해하여야 할 것이다.Although the present invention has been described in detail using preferred embodiments, the scope of the present invention is not limited to specific embodiments, and should be construed by the appended claims. In addition, those skilled in the art will understand that many modifications and variations are possible without departing from the scope of the present invention.

Claims (4)

삭제delete 삭제delete 약재의 열수추출물을 유효성분으로 포함하되,
상기 약재는 향부자 100중량부, 창출 25~40중량부, 진피 25~40중량부, 후박 25~40중량부, 반하 25~40중량부, 적복령 25~40중량부, 연교 25~40중량부, 나복자 25~40중량부, 지실 25~40중량부, 황금 20~30중량부, 황련 20~30중량부, 민들레꽃 10~20중량부 및 달맞이꽃 10~20중량부를 포함하며,
식품 조성물이고,
산에 의해 증가하는 IL-6를 억제하여 식도 세포의 염증반응을 억제하는 것을 특징으로 하는 청위탕 조성물.
Contains hot water extract of medicinal herbs as an active ingredient,
The medicinal material is 100 parts by weight of Hyangbuja, 25-40 parts by weight of creation, 25-40 parts by weight of dermis, 25-40 parts by weight of husk, 25-40 parts by weight of Banha, 25-40 parts by weight of Jeokbokryeong, 25-40 parts by weight of annual bridge, Contains 25-40 parts by weight of licorice, 25-40 parts by weight of branch, 20-30 parts by weight of gold, 20-30 parts by weight of yellow lily, 10-20 parts by weight of dandelion flower and 10-20 parts by weight of evening primrose,
a food composition,
Cheongwi-tang composition, characterized in that it suppresses the inflammatory response of esophageal cells by inhibiting IL-6 increased by acid.
제3항에 있어서,
상기 약재는,
고량강 10~20중량부, 소루쟁이뿌리 10~20중량부, 오수유 10~20중량부, 도꼬마리 열매 10~20중량부 중 1종 이상을 더 포함하는 것을 특징으로 하는 청위탕 조성물.
4. The method of claim 3,
The drug is
Cheongwitang composition, characterized in that it further comprises at least one of 10-20 parts by weight of goryanggang, 10-20 parts by weight of turmeric root, 10-20 parts by weight of osuyu, and 10-20 parts by weight of sagebrush.
KR1020200079498A 2020-06-29 2020-06-29 Cheongwitang Composition KR102412392B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200079498A KR102412392B1 (en) 2020-06-29 2020-06-29 Cheongwitang Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200079498A KR102412392B1 (en) 2020-06-29 2020-06-29 Cheongwitang Composition

Publications (2)

Publication Number Publication Date
KR20220001553A KR20220001553A (en) 2022-01-06
KR102412392B1 true KR102412392B1 (en) 2022-06-24

Family

ID=79347744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200079498A KR102412392B1 (en) 2020-06-29 2020-06-29 Cheongwitang Composition

Country Status (1)

Country Link
KR (1) KR102412392B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101789392B1 (en) 2015-12-31 2017-10-23 대구한의대학교산학협력단 Pharmaceutical composition having extract of rhei rhizoma and glycyrrhizae rhizoma for prevention or treatment of reflux esophagitis
KR20180031180A (en) * 2016-09-19 2018-03-28 이범상 A composition of plants extract for relief of symptoms of gastroesophageal reflux disease and manufacturing method for the same
KR101808328B1 (en) 2017-06-20 2017-12-13 주식회사 성민코리아 Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same
KR102082860B1 (en) 2018-07-17 2020-02-28 주식회사한국야쿠르트 Food composition for prevention and improvment of reflux esophagitis containing Cudrania tricuspidata extract as an effective factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
이영수 외. 개울화담전 (開鬱化痰煎) 이 흰쥐 소장 (小腸) 수송능 (輸送能) 과 위액분비에 미치는 영향. 동의생리병리학회지. 제19권, 5호, 2005, 제1330면-1336면

Also Published As

Publication number Publication date
KR20220001553A (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US8632828B2 (en) Chinese herbal medicine composition used for antiinflammation, detumescence and acesodyne, and preparation method and use thereof
CA2401294C (en) An improved herbal composition having antiallergic properties and a process for the preparation thereof
CN103520578B (en) A kind of Chinese medicine composition for the treatment of oral ulcer and preparation method thereof
KR100981038B1 (en) Composition for treating atopy and acne
KR20110105142A (en) Cosmetic composition with natural orientalplant extract
CN103520502A (en) Chinese medicinal preparation for treating gingivitis and preparation method thereof
KR100968674B1 (en) Herbal composition for alcoholic hangover
CN104399011A (en) Traditional Chinese medicine combination for treating esophageal cancer pain and preparation method thereof
CN103933509B (en) For treating medicine of fresh-water fishes fish molds and preparation method thereof
CN105213941A (en) A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof
KR101961356B1 (en) Composition of Extract of Cirsium Japonicum and Manufacturing method thereof
KR20160131130A (en) The herbal mixture extract as an active ingredient therapeutic compositions for mproving gastrointestinal disorders and indigestion and the therapeutic compositions manufactured thereby
CN114533779A (en) Thymus extract and its use
KR102412392B1 (en) Cheongwitang Composition
CN110652552A (en) Wound healing formula and preparation method
CN111920908B (en) Pharmaceutical composition for treating peptic ulcer
KR100712659B1 (en) Herbal composition for treatment and prevention of diabetes and diabetic complications
World Health Organization Traditional herbal remedies for primary health care
Shrishrimal et al. On barks of Cinnamomomum zeylanicum Nees
KR102246636B1 (en) A composition for antiinflammation comprising natural extracts
CN115607646A (en) Composition for treating recurrent oral ulcer and chronic pharyngolaryngitis and preparation method thereof
CN105663819A (en) Externally applied traditional Chinese medicine preparation for treating bromhidrosis and preparation method
Rahman et al. Trigonella foenum-graecum L
CN104436039A (en) Antitumor preparation for treating gastric cancer and preparation method thereof
KR101368063B1 (en) Pharmaceutical composition for preventing and treatmenting containing of Salvia miltiorrhiza from disease related to renal failure

Legal Events

Date Code Title Description
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant